Corbus Pharmaceuticals (NASDAQ:CRBP) is scheduled to announce its earnings results before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.
Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.45). Corbus Pharmaceuticals had a negative return on equity of 166.99% and a negative net margin of 1,219.36%. The business had revenue of $1.89 million for the quarter, compared to the consensus estimate of $20.97 million. On average, analysts expect Corbus Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
NASDAQ CRBP traded up $0.13 during trading hours on Tuesday, reaching $5.66. 16,344 shares of the company’s stock were exchanged, compared to its average volume of 492,999. The business’s 50-day moving average price is $6.53. Corbus Pharmaceuticals has a one year low of $4.50 and a one year high of $9.11. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.78 and a quick ratio of 1.78. The firm has a market capitalization of $360.98 million, a P/E ratio of -5.71 and a beta of 1.84.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.
Featured Article: How mutual funds make money
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.